Weimar Sepsis Update 2017
8th International Congress "Sepsis and Multiorgan Dysfunction"
Sept 6-8
Abstract
During the last two decades, multiple treatment modalities have been tested in the attempt to improve clinical outcomes from sepsis. During this period we have consistently observed initially promising results that have gradually faded in subsequent large clinical trials. Researchers blame this irreproducibility on slow patient accrual (selection bias), the Hawthorn effect (knowing you are being watched changes your practice), beta-type errors (false positive), publication bias and other factors. In a recent publication (Mebazaa et al. Journal of Intensive Care (2016) 4:24) the authors stated, that the major reasons for lack of survival in recent sepsis trials are over-estimated treatment effects, suboptimal pre-clinical models, incorrect treatment targets, and heterogeneity of definitions and patients. Priorities for future sepsis clinical trials are among others, identification of responders to treatment, networks of sepsis investigators experienced in clinical trial conduct, application of the recent S-3 definitions for sepsis and septic shock, targeted clinical trials in relatively homogeneous groups of patients, and pre-specified covariate adjustment of the primary endpoint (heterogeneity) and exclusion of low-risk patients.
The German Sepsis Society (DSG) will address these questions at its 8th Weimar Sepsis Congress entitled ‘‘Facing the Challenges’’. Why Weimar? Due to its unique features, the Weimar Sepsis Congress has built up a reputation on a national and international level: leading experts from all over the world with excellent publications in basic and clinical research, no parallel sessions—everything under a single roof—vivid discussions in a smooth and casual atmosphere. The 8th Weimar Congress—that will once again take place together with the 9th Congress of the German Society of Intensive Nursing Care—will update you on the current state of knowledge about how to improve treatment of patients by adhering to the guidelines but yet in a critical way.
H. Gerlach
T. Welte
F. M. Brunkhorst
Frank Brunkhorst, Jena, Germany has been the chair at the annual Cytosorbents User Group and is an internationally renowned sepsis researcher who oversees the Cytosorb patient registry at University of Jena and Herwig Gerlach, Berlin, Germany has been a presenter at the User Group as well as ISCEM symposiums on the use of Cytosorb therapy. Both individuals will also be presenters:
Cytokine adsorption in septic shock – Background, rationale and latest data
H. Gerlach, Berlin, Germany
CytoSorb in clinical practice – Individualize your treatment
Z. Molnar, Szeged, Hungary
The CytoSorb Registry – Evidence from real life clinical use
F. Brunkhorst, Jena, Germany
